Initial data from the BEACON study supported the potential for meaningful clinical differentiation of BEAM-101 as compared to currently available treatments for SCD. The data showed that treatment ...
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...